Classes
Publications
- PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated? Czech atherosclerosis society statement2016 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Alirocumab, Praluent(R) in the light of studies2016 | First Faculty of Medicine
- Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel?2011 | First Faculty of Medicine
- SHARP study from the perspective lipidologa2011 | First Faculty of Medicine
- Treatment of HLP and DLP in diabetes2010 | First Faculty of Medicine
- Lipid-lowering treatment in metabolic syndrome2009 | First Faculty of Medicine
- Rosuvastatine2009 | First Faculty of Medicine
- Clinical studies, evidence based medicina expectations and reality2009 | First Faculty of Medicine
- Treatment of HLP and DLP in 20092009 | First Faculty of Medicine
- Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
Loading network view...